NCT00480818View on ClinicalTrials.gov

Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Young and Elderly Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2006

Study Completion Date

July 31, 2007

Conditions
Alzheimer Disease
Interventions
DRUG

SAM-531

Trial Locations (1)

35000

Rennes

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00480818 - Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Young and Elderly Subjects | Biotech Hunter | Biotech Hunter